Non-small cell lung cancer

Detection of early response to chemotherapy by using contrast-enhanced dynamic and diffusion-weighted MR imaging

Hidetake Yabuuchi, Masamitsu Hatakenaka, Koichi Takayama, Yoshio Matsuo, Shunya Sunami, Takeshi Kamitani, Mikako Jinnouchi, Shuji Sakai, Yoichi Nakanishi, Hiroshi Honda

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Purpose: To evaluate the ability of dynamic contrast material-enhanced and diffusion-weighted (DW) magnetic resonance (MR) imaging to help detect early response to chemotherapy in patients with non-small cell lung cancer (NSCLC). Materials and Methods: This study was approved by the institutional review board, and written informed consent was obtained from all subjects. Twenty-eight patients with stage IIIB or IV NSCLC (17 women, 11 men; mean age, 64.8 years) who underwent chemotherapy were enrolled. All patients underwent MR imaging before and after the first course of chemotherapy. The time to peak enhancement, maximum enhancement ratio, and washout ratio were determined from the time-signal intensity curves of dynamic contrast-enhanced MR images. The apparent diffusion coefficient (ADC) of each lung carcinoma was calculated from DW MR images. The responses of these parameters to the first course of chemotherapy and the pretreatment ADC itself were compared with final tumor size reduction by using the Pearson correlation coefficient. Kaplan-Meier curves of progressionfree survival and overall survival were generated, and comparisons between the group with a good response of the significant parameter (upper 50th percentile) and that with a poor response of the significant parameter (lower 50th percentile) were performed by using a two-sided logrank test. Results: Significant correlation was found only between early ADC change and final tumor size reduction rate(r 2 = 0.41, P = .00025). The median progression-free survival for the group with a good increase in ADC was 12.1 months, and that for the group with a stable or decreased ADC was 6.67 months(P = .021), while median overall survival was 22.4 and 12.3 months, respectively(P = .048). Conclusion: ADC seems to be a promising tool for monitoring the early response to or predicting prognosis after chemotherapy of NSCLC.

Original languageEnglish
Pages (from-to)598-604
Number of pages7
JournalRadiology
Volume261
Issue number2
DOIs
Publication statusPublished - Nov 2011

Fingerprint

Diffusion Magnetic Resonance Imaging
Non-Small Cell Lung Carcinoma
Drug Therapy
Magnetic Resonance Spectroscopy
Survival
Research Ethics Committees
Kaplan-Meier Estimate
Informed Consent
Contrast Media
Disease-Free Survival
Neoplasms
Magnetic Resonance Imaging
Carcinoma
Lung

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

Non-small cell lung cancer : Detection of early response to chemotherapy by using contrast-enhanced dynamic and diffusion-weighted MR imaging. / Yabuuchi, Hidetake; Hatakenaka, Masamitsu; Takayama, Koichi; Matsuo, Yoshio; Sunami, Shunya; Kamitani, Takeshi; Jinnouchi, Mikako; Sakai, Shuji; Nakanishi, Yoichi; Honda, Hiroshi.

In: Radiology, Vol. 261, No. 2, 11.2011, p. 598-604.

Research output: Contribution to journalArticle

Yabuuchi, H, Hatakenaka, M, Takayama, K, Matsuo, Y, Sunami, S, Kamitani, T, Jinnouchi, M, Sakai, S, Nakanishi, Y & Honda, H 2011, 'Non-small cell lung cancer: Detection of early response to chemotherapy by using contrast-enhanced dynamic and diffusion-weighted MR imaging', Radiology, vol. 261, no. 2, pp. 598-604. https://doi.org/10.1148/radiol.11101503
Yabuuchi, Hidetake ; Hatakenaka, Masamitsu ; Takayama, Koichi ; Matsuo, Yoshio ; Sunami, Shunya ; Kamitani, Takeshi ; Jinnouchi, Mikako ; Sakai, Shuji ; Nakanishi, Yoichi ; Honda, Hiroshi. / Non-small cell lung cancer : Detection of early response to chemotherapy by using contrast-enhanced dynamic and diffusion-weighted MR imaging. In: Radiology. 2011 ; Vol. 261, No. 2. pp. 598-604.
@article{19f5ce3a0e1d4454a092817a5e9374aa,
title = "Non-small cell lung cancer: Detection of early response to chemotherapy by using contrast-enhanced dynamic and diffusion-weighted MR imaging",
abstract = "Purpose: To evaluate the ability of dynamic contrast material-enhanced and diffusion-weighted (DW) magnetic resonance (MR) imaging to help detect early response to chemotherapy in patients with non-small cell lung cancer (NSCLC). Materials and Methods: This study was approved by the institutional review board, and written informed consent was obtained from all subjects. Twenty-eight patients with stage IIIB or IV NSCLC (17 women, 11 men; mean age, 64.8 years) who underwent chemotherapy were enrolled. All patients underwent MR imaging before and after the first course of chemotherapy. The time to peak enhancement, maximum enhancement ratio, and washout ratio were determined from the time-signal intensity curves of dynamic contrast-enhanced MR images. The apparent diffusion coefficient (ADC) of each lung carcinoma was calculated from DW MR images. The responses of these parameters to the first course of chemotherapy and the pretreatment ADC itself were compared with final tumor size reduction by using the Pearson correlation coefficient. Kaplan-Meier curves of progressionfree survival and overall survival were generated, and comparisons between the group with a good response of the significant parameter (upper 50th percentile) and that with a poor response of the significant parameter (lower 50th percentile) were performed by using a two-sided logrank test. Results: Significant correlation was found only between early ADC change and final tumor size reduction rate(r 2 = 0.41, P = .00025). The median progression-free survival for the group with a good increase in ADC was 12.1 months, and that for the group with a stable or decreased ADC was 6.67 months(P = .021), while median overall survival was 22.4 and 12.3 months, respectively(P = .048). Conclusion: ADC seems to be a promising tool for monitoring the early response to or predicting prognosis after chemotherapy of NSCLC.",
author = "Hidetake Yabuuchi and Masamitsu Hatakenaka and Koichi Takayama and Yoshio Matsuo and Shunya Sunami and Takeshi Kamitani and Mikako Jinnouchi and Shuji Sakai and Yoichi Nakanishi and Hiroshi Honda",
year = "2011",
month = "11",
doi = "10.1148/radiol.11101503",
language = "English",
volume = "261",
pages = "598--604",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "2",

}

TY - JOUR

T1 - Non-small cell lung cancer

T2 - Detection of early response to chemotherapy by using contrast-enhanced dynamic and diffusion-weighted MR imaging

AU - Yabuuchi, Hidetake

AU - Hatakenaka, Masamitsu

AU - Takayama, Koichi

AU - Matsuo, Yoshio

AU - Sunami, Shunya

AU - Kamitani, Takeshi

AU - Jinnouchi, Mikako

AU - Sakai, Shuji

AU - Nakanishi, Yoichi

AU - Honda, Hiroshi

PY - 2011/11

Y1 - 2011/11

N2 - Purpose: To evaluate the ability of dynamic contrast material-enhanced and diffusion-weighted (DW) magnetic resonance (MR) imaging to help detect early response to chemotherapy in patients with non-small cell lung cancer (NSCLC). Materials and Methods: This study was approved by the institutional review board, and written informed consent was obtained from all subjects. Twenty-eight patients with stage IIIB or IV NSCLC (17 women, 11 men; mean age, 64.8 years) who underwent chemotherapy were enrolled. All patients underwent MR imaging before and after the first course of chemotherapy. The time to peak enhancement, maximum enhancement ratio, and washout ratio were determined from the time-signal intensity curves of dynamic contrast-enhanced MR images. The apparent diffusion coefficient (ADC) of each lung carcinoma was calculated from DW MR images. The responses of these parameters to the first course of chemotherapy and the pretreatment ADC itself were compared with final tumor size reduction by using the Pearson correlation coefficient. Kaplan-Meier curves of progressionfree survival and overall survival were generated, and comparisons between the group with a good response of the significant parameter (upper 50th percentile) and that with a poor response of the significant parameter (lower 50th percentile) were performed by using a two-sided logrank test. Results: Significant correlation was found only between early ADC change and final tumor size reduction rate(r 2 = 0.41, P = .00025). The median progression-free survival for the group with a good increase in ADC was 12.1 months, and that for the group with a stable or decreased ADC was 6.67 months(P = .021), while median overall survival was 22.4 and 12.3 months, respectively(P = .048). Conclusion: ADC seems to be a promising tool for monitoring the early response to or predicting prognosis after chemotherapy of NSCLC.

AB - Purpose: To evaluate the ability of dynamic contrast material-enhanced and diffusion-weighted (DW) magnetic resonance (MR) imaging to help detect early response to chemotherapy in patients with non-small cell lung cancer (NSCLC). Materials and Methods: This study was approved by the institutional review board, and written informed consent was obtained from all subjects. Twenty-eight patients with stage IIIB or IV NSCLC (17 women, 11 men; mean age, 64.8 years) who underwent chemotherapy were enrolled. All patients underwent MR imaging before and after the first course of chemotherapy. The time to peak enhancement, maximum enhancement ratio, and washout ratio were determined from the time-signal intensity curves of dynamic contrast-enhanced MR images. The apparent diffusion coefficient (ADC) of each lung carcinoma was calculated from DW MR images. The responses of these parameters to the first course of chemotherapy and the pretreatment ADC itself were compared with final tumor size reduction by using the Pearson correlation coefficient. Kaplan-Meier curves of progressionfree survival and overall survival were generated, and comparisons between the group with a good response of the significant parameter (upper 50th percentile) and that with a poor response of the significant parameter (lower 50th percentile) were performed by using a two-sided logrank test. Results: Significant correlation was found only between early ADC change and final tumor size reduction rate(r 2 = 0.41, P = .00025). The median progression-free survival for the group with a good increase in ADC was 12.1 months, and that for the group with a stable or decreased ADC was 6.67 months(P = .021), while median overall survival was 22.4 and 12.3 months, respectively(P = .048). Conclusion: ADC seems to be a promising tool for monitoring the early response to or predicting prognosis after chemotherapy of NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=80054791611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054791611&partnerID=8YFLogxK

U2 - 10.1148/radiol.11101503

DO - 10.1148/radiol.11101503

M3 - Article

VL - 261

SP - 598

EP - 604

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 2

ER -